FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2141737197> ?p ?o ?g. }

• W2141737197 endingPage "146" @default.
• W2141737197 startingPage "137" @default.
• W2141737197 abstract "This randomized, double-blind study assessed the antifracture efficacy and safety of intermittent intravenous (IV) ibandronate versus oral daily risedronate in Japanese patients with primary osteoporosis. Ambulatory patients aged ≥60 years were randomized to receive 0.5 or 1 mg/month IV ibandronate plus oral daily placebo or 2.5 mg/day oral risedronate, the licensed dose in Japan, plus IV placebo. The primary end point was noninferiority of ibandronate versus risedronate for first new or worsening vertebral fracture over 3 years. A total of 1,265 patients were randomized. A total of 1,134 patients formed the per-protocol set. Both ibandronate doses were noninferior to risedronate: 0.5 mg, hazard ratio (HR) 1.09 [95 % confidence interval (CI) 0.77–1.54]; 1 mg, HR 0.88 (95 % CI 0.61–1.27). The rate of first new vertebral fracture over 3 years was 16.8 % (95 % CI 12.8–20.8) for 0.5 mg ibandronate, 11.6 % (95 % CI 8.2–15.0) for 1 mg ibandronate, and 13.2 % (95 % CI 9.6–16.9) for risedronate. Significant increases in bone mineral density relative to baseline were observed with all treatments after 6 months, with substantial reductions in bone turnover markers after 3 months. Greatest efficacy was obtained with 1 mg ibandronate. Analyses in women only showed similar results to the overall population. No new safety concerns were identified. This study demonstrated the noninferiority of IV ibandronate to the licensed Japanese dose of oral risedronate and suggested that 1 mg/month is an effective dose in Japanese patients with primary osteoporosis." @default.
• W2141737197 created "2016-06-24" @default.
• W2141737197 creator A5021076200 @default.
• W2141737197 creator A5025363249 @default.
• W2141737197 creator A5032025192 @default.
• W2141737197 creator A5045552010 @default.
• W2141737197 creator A5055570113 @default.
• W2141737197 creator A5079499023 @default.
• W2141737197 creator A5088773176 @default.
• W2141737197 date "2013-05-05" @default.
• W2141737197 modified "2023-09-29" @default.
• W2141737197 title "Clinical Efficacy on Fracture Risk and Safety of 0.5 mg or 1 mg/month Intravenous Ibandronate Versus 2.5 mg/day Oral Risedronate in Patients with Primary Osteoporosis" @default.
• W2141737197 cites W1510857267 @default.
• W2141737197 cites W1526826623 @default.
• W2141737197 cites W1568779156 @default.
• W2141737197 cites W1967678736 @default.
• W2141737197 cites W1970071306 @default.
• W2141737197 cites W2006988435 @default.
• W2141737197 cites W2016667123 @default.
• W2141737197 cites W2017797540 @default.
• W2141737197 cites W2021171538 @default.
• W2141737197 cites W2022429253 @default.
• W2141737197 cites W2024412436 @default.
• W2141737197 cites W2026820851 @default.
• W2141737197 cites W2031767761 @default.
• W2141737197 cites W2040116426 @default.
• W2141737197 cites W2047146248 @default.
• W2141737197 cites W2054738028 @default.
• W2141737197 cites W2069811152 @default.
• W2141737197 cites W2074677838 @default.
• W2141737197 cites W2076292373 @default.
• W2141737197 cites W2085517891 @default.
• W2141737197 cites W2090250841 @default.
• W2141737197 cites W2093048881 @default.
• W2141737197 cites W2099054178 @default.
• W2141737197 cites W2102123887 @default.
• W2141737197 cites W2109465803 @default.
• W2141737197 cites W2114344041 @default.
• W2141737197 cites W2124527463 @default.
• W2141737197 cites W2159880200 @default.
• W2141737197 cites W2917781841 @default.
• W2141737197 doi "https://doi.org/10.1007/s00223-013-9734-6" @default.
• W2141737197 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3717162" @default.
• W2141737197 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23644930" @default.
• W2141737197 hasPublicationYear "2013" @default.
• W2141737197 type Work @default.
• W2141737197 sameAs 2141737197 @default.
• W2141737197 citedByCount "55" @default.
• W2141737197 countsByYear W21417371972014 @default.
• W2141737197 countsByYear W21417371972015 @default.
• W2141737197 countsByYear W21417371972016 @default.
• W2141737197 countsByYear W21417371972017 @default.
• W2141737197 countsByYear W21417371972018 @default.
• W2141737197 countsByYear W21417371972019 @default.
• W2141737197 countsByYear W21417371972020 @default.
• W2141737197 countsByYear W21417371972021 @default.
• W2141737197 countsByYear W21417371972022 @default.
• W2141737197 countsByYear W21417371972023 @default.
• W2141737197 crossrefType "journal-article" @default.
• W2141737197 hasAuthorship W2141737197A5021076200 @default.
• W2141737197 hasAuthorship W2141737197A5025363249 @default.
• W2141737197 hasAuthorship W2141737197A5032025192 @default.
• W2141737197 hasAuthorship W2141737197A5045552010 @default.
• W2141737197 hasAuthorship W2141737197A5055570113 @default.
• W2141737197 hasAuthorship W2141737197A5079499023 @default.
• W2141737197 hasAuthorship W2141737197A5088773176 @default.
• W2141737197 hasBestOaLocation W21417371971 @default.
• W2141737197 hasConcept C126322002 @default.
• W2141737197 hasConcept C126894567 @default.
• W2141737197 hasConcept C141071460 @default.
• W2141737197 hasConcept C142724271 @default.
• W2141737197 hasConcept C168563851 @default.
• W2141737197 hasConcept C203092338 @default.
• W2141737197 hasConcept C204787440 @default.
• W2141737197 hasConcept C207103383 @default.
• W2141737197 hasConcept C27081682 @default.
• W2141737197 hasConcept C2776541429 @default.
• W2141737197 hasConcept C2777251235 @default.
• W2141737197 hasConcept C2908647359 @default.
• W2141737197 hasConcept C44249647 @default.
• W2141737197 hasConcept C71924100 @default.
• W2141737197 hasConcept C99454951 @default.
• W2141737197 hasConceptScore W2141737197C126322002 @default.
• W2141737197 hasConceptScore W2141737197C126894567 @default.
• W2141737197 hasConceptScore W2141737197C141071460 @default.
• W2141737197 hasConceptScore W2141737197C142724271 @default.
• W2141737197 hasConceptScore W2141737197C168563851 @default.
• W2141737197 hasConceptScore W2141737197C203092338 @default.
• W2141737197 hasConceptScore W2141737197C204787440 @default.
• W2141737197 hasConceptScore W2141737197C207103383 @default.
• W2141737197 hasConceptScore W2141737197C27081682 @default.
• W2141737197 hasConceptScore W2141737197C2776541429 @default.
• W2141737197 hasConceptScore W2141737197C2777251235 @default.
• W2141737197 hasConceptScore W2141737197C2908647359 @default.
• W2141737197 hasConceptScore W2141737197C44249647 @default.
• W2141737197 hasConceptScore W2141737197C71924100 @default.
• W2141737197 hasConceptScore W2141737197C99454951 @default.
• W2141737197 hasIssue "2" @default.

• next